An increased B-type natriuretic peptide in the absence of a cardiac abnormality identifies those whose left ventricular mass will increase over time

JACC: Heart Failure

Volumn 3, Issue 1, 2015, Pages 87-93

  Nadir, M Adnan ^a   Gandy, Stephen ^a   Ireland, Sheila ^a   MacDonald, Tom ^a   Dow, Ellie ^a   Houston, Graeme ^a   Lang, Chim ^a   Struthers, Allan ^a  

^a NINEWELLS HOSPITAL   (United Kingdom)

Author keywords

B type natriuretic peptide; Hypertension; Left ventricular mass; Primary prevention

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; MALE; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; UPREGULATION; BLOOD; BLOOD PRESSURE; DISEASE COURSE; ECHOGRAPHY; FOLLOW UP; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HEART VENTRICLE; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RETROSPECTIVE STUDY; TIME;

BLOOD PRESSURE; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MAGNETIC RESONANCE IMAGING, CINE; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RETROSPECTIVE STUDIES; STROKE VOLUME; TIME FACTORS; VENTRICULAR FUNCTION, LEFT;

EID: 84920276805     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2014.07.012     Document Type: Article

References (22)

1. Nadir M.A., Rekhraj S., Wei L., et al. Improving the primary prevention of cardiovascular events by using biomarkers to identify individuals with silent heart disease. JAm Coll Cardiol 2012, 60:960-968.
2. Paget V., Legedz L., Gaudebout N., et al. N-terminal pro-brain natriuretic peptide: a powerful predictor of mortality in hypertension. Hypertension 2011, 57:702-709.
3. de Lemos J.A., McGuire D.K., Drazner M.H. B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.
4. McKie P.M., Rodeheffer R.J., Cataliotti A., et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006, 47:874-880.
5. Wang T.J., Larson M.G., Levy D., et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. NEngl J Med 2004, 350:655-663.
6. McDonagh T.A., Cunningham A.D., Morrison C.E., et al. Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart 2001, 86:21-26.
7. Ang D.S., Kong C.F., Kao M.P., Struthers A.D. Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. Am Heart J 2009, 158:133-140.
8. Patton K.K., Heckbert S.R., Alonso A., et al. N-terminal pro-B-type natriuretic peptide as a predictor of incident atrial fibrillation in the Multi-Ethnic Study of Atherosclerosis: the effects of age, sex and ethnicity. Heart 2013, 99:1832-1836.
9. Rekhraj S., Gandy S.J., Szwejkowski B.R., et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. JAm Coll Cardiol 2013, 61:926-932.
10. Kao M.P., Ang D.S., Gandy S.J., et al. Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease. JAm Soc Nephrol 2011, 22:1382-1389.
11. Lieb W., Xanthakis V., Sullivan L.M., et al. Longitudinal tracking of left ventricular mass over the adult life course: clinical correlates of short- and long-term change in the Framingham offspring study. Circulation 2009, 119:3085-3092.
12. Cheng S., Xanthakis V., Sullivan L.M., et al. Correlates of echocardiographic indices of cardiac remodeling over the adult life course: longitudinal observations from the Framingham Heart Study. Circulation 2010, 122:570-578.
13. Verdecchia P., Angeli F., Gattobigio R., Sardone M., Pede S., Reboldi G.P. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypertens 2006, 19:493-499.
14. Verdecchia P., Schillaci G., Borgioni C., et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998, 97:48-54.
15. Tsang T.S., Barnes M.E., Gersh B.J., et al. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. JAm Coll Cardiol 2003, 42:1199-1205.
16. Nadir M.A., Witham M.D., Szwejkowski B.R., Struthers A.D. Meta-analysis of B-type natriuretic peptide's ability to identify stress induced myocardial ischemia. Am J Cardiol 2011, 107:662-667.
17. Welsh P., Poulter N.R., Chang C.L., Sever P.S., Sattar N. The value of N-terminal pro-B-type natriuretic peptide in determining antihypertensive benefit: observations from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension 2014, 63:507-513. ASCOT Investigators.
18. Nishikimi T., Yoshihara F., Morimoto A., et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996, 28:22-30.
19. Suzuki M., Yamamoto K., Watanabe S., Iwata T., Hamada M., Hiwada K. Association between elevated brain natriuretic peptide levels and the development of left ventricular hypertrophy in patients with hypertension. Am J Med 2000, 108:627-633.
20. Struthers A.D. Anew approach to residual risk in treated hypertension-3P screening. Hypertension 2013, 62:236-239.
21. Simpson H.J., Gandy S.J., Houston J.G., Rajendra N.S., Davies J.I., Struthers A.D. Left ventricular hypertrophy: reduction of blood pressure already in the normal range further regresses left ventricular mass. Heart 2010, 96:148-152.
22. Ledwidge M., Gallagher J., Conlon C., et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013, 310:66-74.